TFA Therapeutics (RAJAF) Total Current Liabilities (2020 - 2025)

TFA Therapeutics has reported Total Current Liabilities for 6 years, with the latest figure at $5.2 million in Q4 2025.

• On a quarterly basis, Total Current Liabilities rose 4.12% year-over-year to $5.2 million in Q4 2025; TTM through Dec 2025 was $5.2 million, a 4.12% increase from a year earlier, with the FY2025 full-year figure at $5.2 million, up 4.12% from the prior year.
• Total Current Liabilities was $5.2 million for Q4 2025 at TFA Therapeutics, up from $5.0 million in the prior quarter.
• The five-year high for Total Current Liabilities was $5.2 million in Q4 2025, with the low at $1.5 million in Q3 2023.
• Average Total Current Liabilities over 5 years is $3.3 million, with a median of $2.9 million recorded in 2021.
• The sharpest annual moves came in 2022 and 2024: Total Current Liabilities fell 13.71% in 2022, then surged 68.12% in 2024.
• Over 5 years, Total Current Liabilities stood at $2.9 million in 2021, then dropped by 13.71% to $2.5 million in 2022, then rose by 17.65% to $3.0 million in 2023, then soared by 68.12% to $5.0 million in 2024, then grew by 4.12% to $5.2 million in 2025.
• The last three Total Current Liabilities figures came in at $5.2 million (Q4 2025), $5.0 million (Q4 2024), and $3.0 million (Q4 2023), per Business Quant data.